Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

sLOX-1 in Ischemic Stroke & Transient Ischemic Attack

J Am Heart Assoc; ePub 2018 Jan 12; Skarpengland, et al

Soluble lectin-like oxidized low-density lipoprotein receptor-1 (sLOX-1) levels are elevated in patients with ischemic stroke and transient ischemic attack (TIA) independent of cause and time since the ischemic event, a recent study found. Plasma sLOX-1 (n=232) and carotid plaque OLR1 gene expression (n=146) were evaluated in patients referred for carotid endarterectomy, as well as in health control plasma (n=81). Patients were categorized according to presence of acute ischemic stroke or TIA (n=35), ≤7 days, >7 days ≤3 months (n=90), >3 months (n=40), or no reported symptoms (n=67). Researchers found:

  • Patients with carotid atherosclerosis had increased plasma sLOX-1 levels compared with controls.
  • Plaque OLR1 mRNA levels were increased in carotid plaques compared with nonatherosclerosis vessels.
  • Patients with an acute ischemic stroke caused by atrial fibrillation had raised sLOX‐1 levels comparable to those with an acute ischemic cerebral event related to carotid atherosclerosis.
  • There were no differences in sLOX plasma levels or OLR1 gene expression when analyzed according to the time since relevant cerebral ischemic symptoms.
  • Patients with severe carotid atherosclerosis without any previous ischemic events had raised sLOX-1 levels.


Skarpengland T, Skjelland M, Kong XY, et al. Increased levels of lectin-like oxidized low-density lipoprotein receptor-1 in ischemic stroke and transient ischemic attack. [Published online ahead of print January 12, 2018]. J Am Heart Assoc. doi:10.1161/JAHA.117.006479.

This Week's Must Reads

Anticoagulation in Patients with AF and HF, Clin Cardiol; ePub 2018 Dec 23; Contreras, et al

Serum Uric Acid, Silent MI & Mortality, Am J Cardiol; ePub 2018 Dec 19; Ahmad, et al

Catheter Ablation for AF in Adults with CHD, Heart Rhythm; ePub 2018 Dec 26; Liang, et al

Cognitive Impairment in Adults with Incident HF, J Card Fail; ePub 2018 Dec 22; Sterling, et al

LDL-C Level Reduction Consistent with Evolocumab , JAMA Cardiol; ePub 2018 Dec 12; Qamar, et al

Must Reads in Hypercholesterolemia

LDL-C Level Reduction Consistent with Evolocumab , JAMA Cardiol; ePub 2018 Dec 12; Qamar, et al

Hypertriglyceridemia in Statin-Treated Adults, J Clin Lipidol; ePub 2018 Dec 1; Fan, et al

AHA Statement: Statin Safety & Adverse Events, Arterioscler Thromb Vasc Biol; ePub 2018 Dec 10; Newman, et al

LDL-C Reduction & Arterial Wall Inflammation, Eur Heart J; ePub 2018 Dec 18; Stiekema, et al

Holiday Season and Risk of Hypercholesterolemia, Atherosclerosis; ePub 2018 Dec 19; Vedel-Krogh, et al